A recent real-life study conducted in Romania, aimed at assessing CV risk in individuals with T2D, found that SGLT2ins and GLP-1 RAs were prescribed in a total of 29.4% of T2D cases [30]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.